![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 7 of 7. This is the beginning of the thread.
Posted by iforgotmypassword on August 25, 2009, at 11:15:13
i don't think i have seen this posted.
http://www.reuters.com/article/marketsNews/idUSLU62188920090730
very frustrating.
Posted by Phillipa on August 25, 2009, at 12:27:18
In reply to bifeprunox dropped, posted by iforgotmypassword on August 25, 2009, at 11:15:13
Were you planning on trying this med? So that is who Lundbeck is. Phillipa
Posted by SLS on August 25, 2009, at 13:02:45
In reply to bifeprunox dropped, posted by iforgotmypassword on August 25, 2009, at 11:15:13
Yeah. That does suck. It might have been a better Abilify-type drug as an adjunct medication for major depressive disorder and bipolar depression. Perhaps without the weight gain?
Unfortunately, it seems that DA partial agonists like Abilify and bufeprunox don't make the best antipsychotics when used as monotherapy to treat schizoid disorders. They are real good as an adjunct for negative symptoms, though.
- Scott
Posted by jrbecker76 on August 25, 2009, at 22:52:44
In reply to Re: bifeprunox dropped » iforgotmypassword, posted by SLS on August 25, 2009, at 13:02:45
> Yeah. That does suck. It might have been a better Abilify-type drug as an adjunct medication for major depressive disorder and bipolar depression. Perhaps without the weight gain?
>
> Unfortunately, it seems that DA partial agonists like Abilify and bufeprunox don't make the best antipsychotics when used as monotherapy to treat schizoid disorders. They are real good as an adjunct for negative symptoms, though.
>
>
> - ScottSpeaking of Abilify, Otsuka is currently in trials testing a tweaked version of the Aripiprazole compound. It's most likely a metabolite or an enantiomer of the current molecule. Innovative, eh.
Posted by yxibow on August 26, 2009, at 0:00:27
In reply to bifeprunox dropped, posted by iforgotmypassword on August 25, 2009, at 11:15:13
> i don't think i have seen this posted.
>
> http://www.reuters.com/article/marketsNews/idUSLU62188920090730
>
> very frustrating.Its been kicking around for a while... but yes, in general I agree its frustrating that the pace of mental health agents are slower than others.
-- Jay
Posted by yxibow on August 26, 2009, at 0:14:28
In reply to Re: bifeprunox dropped » iforgotmypassword, posted by SLS on August 25, 2009, at 13:02:45
Forgot to add though about the pace of psychotropics... for every person who tries an agent just out of the pharmacy, they are the first Phase IV patients.
That means complete in real life situations with people already on other medications not already in the studies.
Would I want to be the first to try something that my doctor hasn't heard much chatter about yet ? I'm not really sure considering I've been through rough side effects of things.
Yet, Saphris (asenapine) does peak my curiosity...
Will it be a more liable or less liable (side effect, potential long term effect risks) atypical since it is molecularly completely different from other agents.
Invega I could already put at the top of liability since its basically Risperdal, its nothing new.
And there have been more proven tardive cases with Risperdal (at least at substantial doses) than other medications since it grabs the strongest hold on D2 of atypicals.
As I see it now its sort of {Risperdal/Invega}-> Geodon->Abilify->Zyprexa->Seroquel->{Clozaril}.
But this of course doesn't apply to everyone, just how I would see it possibly apply to myself, being unusually sensitive to APs. I don't even want to think about what happened with Zyprexa..
And people with affective disorders tend to be more prone to EPS and other issues with APs than those with schizophrenia, in general.
-- tidings
Posted by SLS on August 26, 2009, at 6:51:35
In reply to Re: bifeprunox dropped, posted by jrbecker76 on August 25, 2009, at 22:52:44
> > Yeah. That does suck. It might have been a better Abilify-type drug as an adjunct medication for major depressive disorder and bipolar depression. Perhaps without the weight gain?
> >
> > Unfortunately, it seems that DA partial agonists like Abilify and bufeprunox don't make the best antipsychotics when used as monotherapy to treat schizoid disorders. They are real good as an adjunct for negative symptoms, though.
> >
> >
> > - Scott
>
> Speaking of Abilify, Otsuka is currently in trials testing a tweaked version of the Aripiprazole compound. It's most likely a metabolite or an enantiomer of the current molecule. Innovative, eh.I hope it comes to fruition. It would be great if this new drug were to spare us of the latent, insidious weight gain that Abilify produces.
As usual, thank you for providing PB with so much information and the hope that we might find wellness in the drugs that are on their way. We could use a few more D2/D3 partial agonists.
I looked at the data from some of the clinical studies of bifeprunox. Unfortunately, they were very disappointing. I really never expected it to be approved.
- Scott
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.